The Role and Potential of Imaging in COPD

George R. Washko, MD, MS

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a condition defined as incompletely reversible expiratory airflow obstruction caused by the exposure of noxious inhaled particulates.1 Although the severity of the disease is assessed by the degree of lung function impairment, it is increasingly clear that COPD is a syndrome with numerous pulmonary and extrapulmonary manifestations, such as the emphysematous destruction of the lung parenchyma, lung cancer, remodeling of the airways and vasculature, cardiac impairment,2 cachexia, and bone demineralization.3 There is great interest in the clinical and research communities to refine our understanding of the potential association of these processes and it is thought that imaging may provide some of that insight.

The following article reviews the insights gained by imaging in smoking-related COPD. The unique contributions of various imaging modalities, such as computed

KEYWORDS

• COPD • Imaging • CT scan • MRI • PET • OCT

KEY POINTS

• New-generation computerized tomography with the visualization of lung parenchyma, airways, and vessels has helped clarify the association between radiological changes and clinical phenotypes.
• In chronic obstructive pulmonary disease (COPD), radiological phenotyping has been instrumental in the development of therapies, such as surgical and bronchoscopic lung volume reduction.
• The expansion of the knowledge of COPD using the integration of the data obtained through imaging and function will likely help plan therapeutic trials, such as regenerative therapy.
• The advent of radiological techniques capable of providing detailed information about lung structure and function is providing new insight into disease pathophysiology which may lead to improvements in clinical care.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a condition defined as incompletely reversible expiratory airflow obstruction caused by the exposure of noxious inhaled particulates.1 Although the severity of the disease is assessed by the degree of lung function impairment, it is increasingly clear that COPD is a syndrome with numerous pulmonary and extrapulmonary manifestations, such as the emphysematous destruction of the lung parenchyma, lung cancer, remodeling of the airways and vasculature, cardiac impairment,2 cachexia, and bone demineralization.3 There is great interest in the clinical and research communities to refine our understanding of the potential association of these processes and it is thought that imaging may provide some of that insight.

The following article reviews the insights gained by imaging in smoking-related COPD. The unique contributions of various imaging modalities, such as computed

Dr Washko was supported by grant K23 HL089353 and an award from the Parker B. Francis Foundation.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
E-mail address: GWashko@Partners.org

doi:10.1016/j.mcna.2012.05.003 medical.theclinics.com
0025-7125/12/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
tomography (CT), magnetic resonance imaging (MRI), optical coherence tomography (OCT), and positron emission tomography (PET), to a better understanding parenchymal, airway, and vascular disease is explored. Finally, the current and future contributions of imaging to clinical care are discussed.

CT

Parenchymal Disease

Smoking-related destruction of the lung parenchyma is typically thought to manifest as emphysema. Defined by its appearance in the secondary pulmonary lobule (the most fundamental structural component of the lung containing airways, lymphatics, vasculature, and parenchyma encapsulated in connective tissue), emphysema is visually classified as being centrilobular, panlobular, and paraseptal disease. Initial roentgenologic studies of the lungs of smokers identified several cardiac signs for the presence of emphysema, such as increased lucency of the lung fields, narrowing of the cardiac silhouette, and pruning of the peripheral vasculature (Fig. 1). Such findings are sensitive but lack the specificity required for large-scale clinical and research applications.

With the introduction of CT into the medical sciences in the late 1970s, it became possible to visualize lung structure in vivo. One of the first applications of these imaging modalities was to develop subjective and objective methods for the assessment of emphysema. Termed density mask analysis, Muller and colleagues defined a Hounsfield unit threshold in the CT image that dichotomized the lung into emphysematous (density less than that Hounsfield unit threshold) and nonemphysematous (density greater than that Hounsfield unit threshold) tissue. This type of densitometric analysis was found to be predictive of clinically significant metrics of disease, such as lung function, and correlated with histopathologic assessments of emphysema on explanted lung tissue. With the caveat that the Hounsfield unit threshold used to delineate emphysematous from nonemphysematous tissue is subject to the image acquisition and reconstruction parameters, densitometric analysis of the lung parenchyma has become a cornerstone of radiologic characterization of lung disease.

Fig. 1. (A, B) PA and Lateral chest radiograph of a patient with severe COPD and emphysema. Note the lucency of the lung fields, flattening of the diaphragms, narrowed cardiac silhouette, and paucity of peripheral vascular markings.
in smokers (Fig. 2). Although densitometric analysis of the lung may provide global-, regional-, and lobar-specific measures of emphysema on the CT scan, when applied across a large region of lung, a major limitation is its relative inability to differentiate emphysema subtype (centrilobular, panlobular, and so forth). This limitation is most apparent when performing a head-to-head comparison of this technique with visual inspection of the lung parenchyma. Although the visual analysis of the lung parenchyma suffers from intraobserver and interobserver variability, in several investigations it has been demonstrated to correlate with the pathologic condition, lung function, and predict the outcome in clinical investigations. In an effort to address this, the community of radiological and computer scientists has focused on developing techniques that may objectively identify the emphysema type and distribution. These techniques are based largely on patterns of local features in the secondary pulmonary lobule and, for the purposes of this article, are collectively called textural analysis.

Texture analysis of the lung involves the selection of a discrete region of interest within the lung field and then assessing several parameters in this constrained region, such as density and the patterns of changes in density. Using such an approach,

Fig. 2. (A, C) A coronal view of the lungs of a smoker with normal lung function (A) and one with moderate emphysema (C). (B, D) Volumetric reconstructions of the left lung pulmonary vasculature from a left midaxillary view. Vessels are color coded by diameter. Notice the loss of vasculature and thinning of the vessels in regions most affected by emphysema.
several groups of investigators have demonstrated that this technique could accurately identify disease type (using visual analysis as a gold standard) and provide more robust measures of lung disease for correlation in clinical investigations. Indeed Xu and colleagues demonstrated that such a technique could provide information that surpassed that provided by visual inspection. Although the sensitivity of textural analysis is potentially superior to visual inspection, it is computationally costly; until a more parsimonious approach to tissue classification is developed, it is limited to smaller-scale investigations.

Finally, it is increasingly clear that the manifestations of smoking-related parenchymal disease are not limited to low-attenuating tissue on the CT scan. Recently, Lederer and colleagues demonstrated that a subset of smokers are more likely to have high-attenuating inflammatory, fibrotic, and atelectatic regions of the lung that are associated with a restrictive spirometric pattern of lung function. In a subsequent study, these lesions were found to be associated with reductions in lung volume and were inversely associated with emphysema. Those smokers with such interstitial lung abnormalities (ILA) also tended to have pseudonormalization of their spirometry, likely from the mitigating effects of these abnormalities on reduced lung elastic recoil caused by emphysema. Further work is needed to determine the complete nature of ILA in smokers, but a subset of these patients may progress to clinically overt interstitial lung disease. Also, given the common noxious exposure (tobacco smoke), a deeper understanding of the mechanisms that lead the lung down a fibrotic rather than emphysematous pathway of remodeling may offer insight into overall disease susceptibility.

**Airway Disease**

In obstructive lung disease, the site of expiratory airflow limitation is thought to be the small airways, those less than 2 mm in diameter. Although this is beyond the resolution of clinical CT scanning, prior investigation suggests that radiological assessments of the central airways reflects remodeling in the lung periphery. There are several metrics of central airway morphology in smokers. These metrics include the external or total bronchial area, the wall area (WA), the lumen area (Ai), the wall thickness, and the wall area percent (WA%; 100 \* [WA]/[Ai + WA]). In one of the first systematic analyses of airway morphology in smokers, Nakano and colleagues assessed the apical segment of the right upper lobe (RB1) in 114 smokers. In their analysis, they found that those patients with the greatest WA% (increased ratio of WA to Ai) had the lowest forced expiratory volume in the first second of expiration expressed as a percent of the predicted. Based on this investigation, the WA% has become the most commonly used metric for clinical investigation largely because it has consistently provided the strongest correlation to spirometric measures of lung function. In a subsequent investigation, this same group demonstrated that central airway remodeling apparent on CT reflected distal histopathologic remodeling of the small airways, those with great central airway wall thickening had more small airway disease. More recent work has suggested that the more peripheral the radiological assessments of airway structure in smokers (measures performed in airway generations closer to the small airways), the stronger the correlation with lung function. Although this finding has compelled investigators to examine more and more distal airways, such measures are limited by the resolution of the CT images. For this reason, the most accurate measures of airway morphology are obtained from the third-generation segmental and possibly fourth-generation subsegmental airways.

Investigators have begun to look beyond airway wall thickening to assess airway disease in smokers. Included in these efforts are quantitative assessments of mural density or attenuation. The premise behind these investigations is that as an airway
wall thickens or remodels, both the shape and contents of the wall change. Normal bronchial cartilage may be gained or lost and normal connective tissue replaced by a scar. Preliminary investigation suggests that airway wall attenuation may provide additional information regarding airway disease in smokers. Further work is needed to comprehensively understand the scanner-to-scanner variability and the influence of body habitus on these measures.

Recently, Hogg and colleagues introduced a new paradigm for airway disease in smokers. Not only does airway remodeling lead to luminal obstruction and expiratory airflow obstruction but there also seems to be an outright loss of airways in advanced COPD. Using micro CT to examine the resected lung tissue, this group demonstrated that patients with advanced emphysema may have lost up to 90% of their terminal bronchioles. In addition to expiratory airway collapse caused by the loss of elastic recoil and fixed luminal obstruction of the small airways, a third potential mechanism for increased resistance to flow is the loss of parallel pathways.

Based on these findings, Diaz and colleagues examined the chest CT scans of 50 smokers enrolled in the Lung Tissue Research Consortium and found that those patients with more advanced emphysema have pruning of the central airways on CT scan (loss of airways in generations 5–8). Further, even after the adjustment for densitometric measures of emphysema, the total airway count (sum of the airway generations visible in the third to eighth generation starting from the apical segment of the RB1) was an independent predictor of the Body mass index, Airflow obstruction, Dyspnea, and Exercise capacity (BODE) score, which is a validated multidimensional measure of mortality in COPD. Further histologic validation is needed to determine the extent to which airway loss manifests in the more proximal airway tree; however, airway dropout may be a marker of the extreme of airway disease.

As CT acquisition times have decreased, it is now feasible to perform more dynamic inspiratory/expiratory CT scanning of the chest. The addition of an expiratory image allows for the quantitative detection of the hallmark of a COPD, gas trapping. Visually, this may appear as mosaicism suggesting local gas trapping caused by an admixture of emphysema and airway disease. Using a Hounsfield unit threshold of -856 (attenuation value for normal), the expiratory image can also be quantitatively assessed whereby all tissue less than this value are designated as exhibiting gas trapping. Although a current limitation of such an approach is the inability to differentiate the effects of emphysema and airway remodeling, new techniques are being developed that may allow for the subtraction of emphysema giving the user a clearer picture of the impact of small airway disease.

Vascular Remodeling

Pulmonary vascular disease is an independent predictor of morbidity and mortality in COPD. It is estimated that 30% to 70% of patients with COPD have clinically significant burdens of disease, and recent work has demonstrated that pathologic pulmonary vascular remodeling is found even in smokers with normal lung function. The mechanisms for this process likely include inflammation, hypoxic vasoconstriction, and outright loss of parallel pathways caused by emphysematous destruction of the tissue. Although the standard visual assessment of pulmonary vascular remodeling includes measurements of the diameter of the main pulmonary artery, more recent investigations have capitalized on the ability of CT imaging to provide detailed measures of structure. These studies have demonstrated that remodeling of the distal intraparenchymal pulmonary vasculature yields compelling insights into the relation of vascular disease and emphysema, the effect of pulmonary vascular disease on pulmonary artery pressure, and a potential link between pulmonary vascular remodeling and atherosclerotic disease.
More recently, Alford and colleagues undertook an investigation of pulmonary vascular remodeling in the earliest stages of smoking-related lung disease. In a cohort of 43 patients (17 healthy, 12 smokers with no emphysema and normal lung function, 12 smokers with mild emphysema), using central venous boluses of iodinated contrast agent, this group was able to demonstrate that pulmonary vascular remodeling could be detected and quantitatively assessed at its earliest stages. Although such an approach is not amenable to population-based studies, the findings of this study are consistent with the hypothesis that emphysema may begin as a vascular disease leading to a regional loss of tissue.

With the advances and large-scale application of CT scanning in clinical investigations, there have been several recent studies that have provided compelling insight into the clinical and functional impact of smoking-related lung disease. For example, using CT scans and epidemiologic and clinical data from the Multi Ethnic Study of Atherosclerosis, Barr and colleagues clearly demonstrated that emphysema and its associated hyperinflation compromises cardiac function through reductions in left ventricular filling, possibly caused by occult pulmonary vascular remodeling. More recently, Han and colleagues depicted the complex relationship between radiological emphysema, airway disease, and acute exacerbations (AECOPD) of COPD. The results of this investigation may allow clinicians and clinical investigators to identify who is at the greatest risk for an AECOPD to enrich both clinical studies and maximize preventive therapies in the outpatient setting. Lastly, to mention one of the most direct applications of CT imaging of the chest in therapeutic intervention, a trial of bronchoscopically placed one-way valves to achieve minimally invasive volume reduction demonstrated that those patients with incomplete interlobar fissures had the lowest chance of procedural benefit likely because of collateral ventilation.

Possibly the greatest critique of CT imaging to date has been the lack of a clear vision of how quantitative assessments of parenchymal, airway, and vascular disease may guide the clinical care of patients with COPD. Although the quantitative CT scan is not yet integrated into clinical practice, the results of several recent investigations have provided a new understanding of the disease, and it is through this understanding that new therapies and therapeutic approaches to care will be discovered. These advances do not come without concern. The clinical and research community is increasingly aware of the risks associated with the radiation exposure necessary for CT acquisition. Although the estimates of the associations between the dose of radiation and the risk of cancer vary, this risk may be as high as 1/80 lifetime risk from a single CT. Finally, mention must be made of the overlap or co-occurrence of lung cancer and COPD. While it is unclear if the origins of cancer are found in airway or parenchymal remodeling it is thought that smokers with COPD who have emphysema on their CT are at the highest risk for developing cancer. There are now several studies using screening CT scans of the chest to determine if early detection and presumably early intervention will reduce cancer-related mortality. One of the largest and most recent studies, the National Lung Screening Trial, found a 20% relative reduction in mortality in patients undergoing annual screening CT scans. Although these results are compelling, there are limitations to screening CT scans. Given the cost of each CT, it is impractical and impossible to screen the general population of smokers. Clearly, further refinements of who is at the greatest risk for the development of cancer need to be undertaken to develop a more focused screening algorithm. Also, screening CT scans of the chest of smokers leads to the detection of a large number of false-positive nodules that may require further evaluation. In addition to the added cost of these procedures comes the morbidity associated with lung biopsy and fiber-optic bronchoscopic approaches to obtaining tissue for histopathology diagnosis.
MRI

The basis for MRI is the perturbation of protons (hydrogen atoms) by a burst of radio waves. A strong magnetic field is applied to the tissue, which aligns the protons within. The brief application of a radio wave then forces these protons out of alignment. The energy emitted by the proton during this process and the process of returning to alignment is detected by the scanner and converted into the image displayed for clinical use. Unlike CT scanning, no ionizing radiation is used to generate the image. Given this obvious advantage, MRI has the potential to perform detailed real-time evaluations of tissue motion, which are then related to global and local tissue mechanics. A limiting factor for the application of MRI to the lung is, however, the lung architecture itself. The lung is primarily a gas-filled structure whose density (and therefore concentration of protons) is less than that of solid organs, such as the brain or liver. Because of this limitation, a good deal of research in lung imaging has been focused on the development and application of inhaled and intravenous contrast agents to enhance data collection.

Parenchyma

Although the strength of CT is its ability to accurately reflect details in tissue architecture, it is limited in its ability to detect function. Generally, tissue that seems normal on the CT scan is assumed to make full contribution to overall lung function. Several recent MRI studies using inhaled hyperpolarized noble gases, such as \(^{3}\)helium (\(^{3}\)He) and \(^{129}\)xenon (\(^{129}\)Xe), have offered new insight into lung structure and function and have great promise for demonstrating the falsity of this assumption.

The promise of hyperpolarized gases for imaging has been known for more than 25 years, and it was not until the late 1990s that their application in pulmonary research began to move toward its true potential.\(^{65}\) To perform such experiments, a sample of helium or xenon is hyperpolarized using a laser and then on inhalation will initially distribute throughout the gas-containing regions of the lung. The initial diffusivity of the gas can then be assessed to provide quantitative information about lung structure, such as mean linear intercept, surface-to-volume ratio, airway radii, and number of alveoli.\(^{66}\) \(^{129}\)Xenon has the added advantage of being freely diffusible across the alveolar capillary membrane, and several investigators have demonstrated that this diffusion and washout in the capillary bed can be readily distinguishable. The integration of these steps, the diffusion of gas into the alveolus, the transfer across the alveolar-capillary membrane, and then removal by capillary blood flow, allows quantitative insight into one of the most basic functions of the lung: matching of ventilation and perfusion.\(^{67–72}\)

Another interesting property of hyperpolarized noble gases is their increased rate of decay in the presence of oxygen. What may seem to be a limitation to pulmonary research has been demonstrated to offer additional information about function. Because of the regional heterogeneity in ventilation perfusion matching in the lung, oxygen tension is not uniform throughout the gas-containing regions of the parenchyma. The detection and quantification of this by measuring the differential rates of decay of \(^{3}\)He or \(^{129}\)Xe allows for an in-vivo assessment of the most fundamental aspect of lung function (Fig. 3).\(^{73–75}\)

Airways

Unlike CT, MRI-based investigations of the airways do not tend to focus on the morphology of the more central tracheobronchial tree. Rather, MRI is more readily used to interrogate the flow of gas throughout the lung. The resulting flow of gas...
(diminished in more diseased areas of the lung) can be quantified and presented as a ventilation defect volume.\textsuperscript{76–79} Such a measure may reflect regions afflicted by either emphysema or airway disease or potentially an admixture of the two. Again, unlike the CT scan, this assessment is not dependent on proximal airway structure reflecting distal remodeling, rather it is a direct measure of the properties of the distal lung parenchyma and small airways.

**Vasculature**

A strength of MRI is its ability to assess organ motion through the continuous or gated acquisition of data. As an example, electrocardiogram-gated MRI has become a standard for the calculation of cardiac function and offers more reproducible investigations of both right and left ventricular function than cardiac echo.\textsuperscript{80–83} Given increasing interest in the interdependence of heart and lung in diseases, such as COPD, an in vivo tool to assess ventricular impairment is of great interest to clinical investigators. MRI also has been used to assess the distensibility of the central vessels.\textsuperscript{84,85} Previous investigations in pulmonary hypertension suggest that such measures offer prognostic value for therapeutic intervention.\textsuperscript{86} Finally, the true source of pulmonary vascular compromise in COPD is likely the distal small vessels. As mentioned previously, remodeling at these sites has been observed even in smokers with normal lung function.\textsuperscript{43,44} Although direct morphologic assessment of the vascular at this level is beyond the resolution of clinical MRI, techniques, such as dynamic contrast-enhanced MRI perfusion, may offer a solution.\textsuperscript{87–89} The premise to this technique is that after an intravenous contrast agent is introduced into the pulmonary arterial circulation, its local concentration will diminish proportionally to the ability of the lung to carry it away in the circulating blood volume. The more prolonged the decline in contrast concentration the lower the regional flow and, therefore, the greater relative regional pulmonary vascular resistance. Such a technique has been applied within pulmonary embolism or suspected pulmonary embolism.\textsuperscript{87,90} Further work is needed to apply and validate this technique to pulmonary vascular disease associated with smoking.

There is great promise in the applications of MRI to investigations of smoking-related lung disease. This comes from both the novel applications of inhaled and intravenous contrast agents and the remarkable ability it provides for resolving lung structure. Recently Kirby and colleagues\textsuperscript{91} demonstrated that in a longitudinal assessment of 20 patients (15 smokers, 5 healthy), \textsuperscript{3}He proved to be a more sensitive measure of disease progression in the smokers over a 2-year period than standard spirometric and plethysmographic measures of lung function. Additional ongoing
work at multiple institutions suggests that these techniques may improve our ability to monitor disease progression and the response to therapy. With time, MRI may play a significant role in both investigation and clinical care of patients with COPD.

**PET**

PET is a nuclear medicine technology based on the detection of regionalized concentrations of a positron emitting radionuclide. The localization of this tracer depends on the type of biologically active molecule that serves as its carrier. A commonly used molecule for clinical medicine is glucose, which is taken up by the most metabolically active tissues. Although PET has been widely used by clinicians for the detection and monitoring of malignancy, its applications in lung disease, such as COPD, have provided new insights into the disease pathology and potentially pathogenesis.

Recently, Vidal Melo and colleagues\(^9\) demonstrated that there is significant heterogeneity of lung perfusion in mild and moderate COPD even after adjusting for regional changes in lung density and ventilation. Similar to work published by Alford and colleagues,\(^4\) these changes in regional perfusion seem to precede visible changes to the lung structure, such as emphysema, suggesting that at least part of the progression of parenchymal disease in COPD is caused by vascular remodeling. Further work is needed to establish the relationship of longitudinal changes in regional lung perfusion and disease progression, but as the investigators suggest, assessments of vascular morphology and perfusion may indeed be a valuable biomarker for COPD.

**OCT**

OCT is an imaging method based on the refraction of light as it passes through tissues. A fiberoptic probe with a light source is introduced into the airways via a bronchoscope and the light patterns reflected by the tissue of interest are then reconstructed into an image. Unlike CT, MRI, or PET, OCT has the ability to resolve structures on the order of micrometers and can essentially provide in vivo images of tissue histology (Fig. 4). The

![Fig. 4. A view using OCT. The fiberoptic probe can be seen at the center. Adjacent to the outer surface of the probe are alveolar ducts and alveoli. (Courtesy of Dr Anthony Lee of the British Columbia Cancer Research Center.)](image-url)
primary strength of OCT is in examining airway morphology, which readily lends itself to airway disease in COPD. Recently, Coxson and colleagues\textsuperscript{93} demonstrated in smokers that although CT measures of airway wall thickness correlate with lung function, it significantly overestimates airway size. OCT was a more sensitive measure of disease and simultaneously provided data on airway wall morphology and subepithelial remodeling and collagen deposition. Although OCT is not amenable to large-scale population-based studies, its ability to detect and monitor airway disease in smokers makes it a natural candidate for the investigation of pharmaceutical agents thought to reduce mural inflammation.\textsuperscript{94}

Although there are definite niches and limitations to the imaging modalities presented in this article, each offers unique strengths and in aggregate has provided new and exciting insight into the potential pathogenesis and physiology of COPD. The greatest contribution to imaging has been its ability to facilitate in vivo investigations in both small cohorts and population-based investigations. It will be some time before MRI, PET, OCT, or even quantitative CT scanning becomes part of standard clinical practice, but they have already become the foundation for most clinical trials. It is clear that spirometric measures of lung function alone do not suffice for disease classification in smokers. They are too insensitive to disease heterogeneity and are only weakly correlated to both the symptoms and functional capacity experienced by patients with COPD. The future of investigation and clinical care lies in a combination of clinical characterization and image-based assessments of lung structure.

REFERENCES


